Prospective study on meglitinide induced kidney injury in tertiary care hospital
1 Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346, India.
2 Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346, India.
3 Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 25(01), 211–219.
Article DOI: 10.30574/gscbps.2023.25.1.0421
Publication history:
Received on 06 September 2023; revised on 17 October 2023; accepted on 20 October 2023
Abstract:
The aim of the study is to conduct a prospective study on meglitinide induced kidney injury in tertiary care hospital. The objective is to evaluate meglitinide, quality of life, mortality, and to evaluate the severity of the adverse drug effect of the meglitinide in diabetic patients. As per the prospective study of “Meglitinide induced kidney injury”. It has been concluded that the prolong intake of meglitinidein diabetic patients leads to increase in serum creatinine levels upto 11 % out of 300 study population. And incidence of kidney injury majorly seen in patients who are taking meglitinidefor a period of 6 – 10 yrs and mostly seen males in age group of 50 – 60 yrs.
Keywords:
Meglitinide; Diabetic; Prospective; Tertiary care; Hospital
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
